2021
Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America
McGinnis KA, Justice AC, Moore RD, Silverberg MJ, Althoff KN, Karris M, Lima VD, Crane HM, Horberg MA, Klein MB, Gange SJ, Gebo KA, Mayor A, Tate JP, Benson C, Bosch R, Kirk G, Marconi V, Colasanti J, Mayer K, Grasso C, Hogg R, Lima V, Montaner J, Sereda P, Salters K, Buchacz K, Li J, Gebo K, Moore R, Moore R, Jacobson J, Horberg M, Silverberg M, Thorne J, Brown T, Tien P, D’Souza G, Smith G, Loutfy M, Gupta M, Klein M, Rabkin C, Kroch A, Burchell A, Betts A, Lindsay J, Nijhawan A, Mayor A, Gill M, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Bamford L, Karris M, Eron J, Napravnik S, Kitahata M, Crane H, Sterling T, Haas D, Rebeiro P, Turner M, McGinnis K, Justice A, Moore R, Althoff K, Gange S, Kitahata M, Lee J, Saag M, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Althoff K, Freeman A, Kitahata M, Van Rompaey S, Crane H, Morton L, McReynolds J, Lober W, Gange S, Lee J, Hogan B, You B, Humes E, Gerace L, Stewart C, Coburn S. Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America. Clinical Infectious Diseases 2021, 75: 297-304. PMID: 34609485, PMCID: PMC9410720, DOI: 10.1093/cid/ciab883.Peer-Reviewed Original ResearchConceptsNorth American AIDS Cohort CollaborationVACS Index 2.0National Death IndexHIV-1 RNAHuman immunodeficiency virusCopies/mLRisk of mortalityRace/ethnicityCohort CollaborationNA-ACCORDCause mortalityCD4 countMedian ageDeath IndexImmunodeficiency virusPredicting MortalityMortality ascertainmentMortality rateMortalitySpecific biomarkersPWHDiverse cohortObserved mortalityCohortHIV
2018
HIV and Age Do Not Synergistically Affect Age-Related T-Cell Markers
Farhadian S, Jalbert E, Deng Y, Goetz MB, Park LS, Justice A, Dubrow R, Emu B. HIV and Age Do Not Synergistically Affect Age-Related T-Cell Markers. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 77: 337-344. PMID: 29140874, PMCID: PMC5807137, DOI: 10.1097/qai.0000000000001595.Peer-Reviewed Original ResearchConceptsCD8 T cellsT-cell markersCD4 T cellsHIV infectionT cellsAntiretroviral therapyEffector memory CD4 T cellsImmune systemVeterans Aging Cohort StudyMemory CD4 T cellsNaive CD4 T cellsAging Cohort StudyT cell subsetsT-cell phenotypeCopies/mLCross-sectional studyRace/ethnicityChronic HIVUninfected subjectsUninfected menCohort studyHIV diseaseHigher proportionHIV serostatusHIV status
2017
Risk of End‐Stage Renal Disease in HIV‐Positive Potential Live Kidney Donors
Muzaale AD, Althoff KN, Sperati CJ, Abraham AG, Kucirka LM, Massie AB, Kitahata MM, Horberg MA, Justice AC, Fischer MJ, Silverberg MJ, Butt AA, Boswell SL, Rachlis AR, Mayor AM, Gill MJ, Eron JJ, Napravnik S, Drozd DR, Martin JN, Bosch RJ, Durand CM, Locke JE, Moore RD, Lucas GM, Segev DL. Risk of End‐Stage Renal Disease in HIV‐Positive Potential Live Kidney Donors. American Journal Of Transplantation 2017, 17: 1823-1832. PMID: 28497525, PMCID: PMC5489376, DOI: 10.1111/ajt.14235.Peer-Reviewed Original ResearchMeSH KeywordsAdultCase-Control StudiesFemaleFollow-Up StudiesGlomerular Filtration RateGraft RejectionGraft SurvivalHIV InfectionsHIV SeropositivityHIV-1HumansIncidenceKidney Failure, ChronicKidney Function TestsKidney TransplantationLiving DonorsMaleMiddle AgedNephrectomyNorth AmericaPrognosisRisk FactorsViral LoadConceptsEnd-stage renal diseaseIncidence of ESRDHIV-positive individualsLive kidney donorsKidney donorsRenal diseaseMultivariable Cox proportional hazards regressionCox proportional hazards regressionPotential live kidney donorsHIV-negative peersHIV-negative participantsHIV-positive participantsProportional hazards regressionCopies/mLKidney donor candidatesCumulative incidence estimatesCohort CollaborationCumulative incidenceHIV infectionViral loadHazards regressionNational HealthPositive individualsIncidence estimatesHealth characteristicsAssociation Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study
Freiberg MS, Chang CH, Skanderson M, Patterson OV, DuVall SL, Brandt CA, So-Armah KA, Vasan RS, Oursler KA, Gottdiener J, Gottlieb S, Leaf D, Rodriguez-Barradas M, Tracy RP, Gibert CL, Rimland D, Bedimo RJ, Brown ST, Goetz MB, Warner A, Crothers K, Tindle HA, Alcorn C, Bachmann JM, Justice AC, Butt AA. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study. JAMA Cardiology 2017, 2: 536-546. PMID: 28384660, PMCID: PMC5541383, DOI: 10.1001/jamacardio.2017.0264.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCase-Control StudiesCD4 Lymphocyte CountCohort StudiesFemaleHeart FailureHIV InfectionsHumansMaleMiddle AgedProportional Hazards ModelsRisk AssessmentRisk FactorsRisk Reduction BehaviorStroke VolumeUnited StatesUnited States Department of Veterans AffairsVeteransViral LoadConceptsRisk of HFrEFHuman immunodeficiency virus (HIV) infectionVeterans Aging Cohort StudyAntiretroviral therapy eraRisk of HFpEFReduced ejection fractionCells/mm3Immunodeficiency virus infectionHeart failureAging Cohort StudyHIV infectionEjection fractionUninfected veteransTherapy eraCohort studyVirus infectionHIV-1 RNA viral loadTime-updated CD4 cell countHIV-specific factorsBaseline cardiovascular diseaseCD4 cell countRNA viral loadCopies/mLRace/ethnicityObservational cohort
2013
Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans
Anderson JP, Tchetgen E, Re V, Tate JP, Williams PL, Seage GR, Horsburgh CR, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Klein MB, Justice AC. Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans. Clinical Infectious Diseases 2013, 58: 719-727. PMID: 24285848, PMCID: PMC3922212, DOI: 10.1093/cid/cit779.Peer-Reviewed Original ResearchConceptsHepatitis C virusInitiation of ARTAntiretroviral therapyHepatic decompensationHazard ratioVeterans Aging Cohort Study Virtual CohortHIV/HCV-coinfected patientsHuman immunodeficiency virus (HIV) coinfectionEnd-stage liver diseaseHepatic decompensation eventsIncident hepatic decompensationLiver disease outcomesCombination antiretroviral therapyImmunodeficiency virus coinfectionHospital discharge diagnosisSpontaneous bacterial peritonitisCopies/mLMarginal structural modelsART initiationART regimenDecompensation eventsHIV RNAVariceal hemorrhageBacterial peritonitisLiver failureHIV Infection and the Risk of Acute Myocardial Infarction
Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Goetz M, Leaf D, Oursler KA, Rimland D, Barradas M, Brown S, Gibert C, McGinnis K, Crothers K, Sico J, Crane H, Warner A, Gottlieb S, Gottdiener J, Tracy RP, Budoff M, Watson C, Armah KA, Doebler D, Bryant K, Justice AC. HIV Infection and the Risk of Acute Myocardial Infarction. JAMA Internal Medicine 2013, 173: 614-622. PMID: 23459863, PMCID: PMC4766798, DOI: 10.1001/jamainternmed.2013.3728.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAcute myocardial infarctionRisk of AMIFramingham risk factorsUninfected veteransRisk factorsMyocardial infarctionAMI eventsHIV statusVeterans Aging Cohort Study Virtual CohortHIV-1 RNA levelsStandard Framingham risk factorsIncident acute myocardial infarctionIncidence of AMISubstance useBaseline cardiovascular diseaseCD4 cell countHepatitis C infectionBody mass indexHIV-1 RNACopies/mLHIV-positive veteransTime-updated analysisDecade of ageRace/ethnicity
2012
HIV Status, Burden of Comorbid Disease, and Biomarkers of Inflammation, Altered Coagulation, and Monocyte Activation
Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, Goetz M, Tracy R, Oursler KK, Rimland D, Crothers K, Rodriguez-Barradas M, Crystal S, Gordon A, Kraemer K, Brown S, Gerschenson M, Leaf DA, Deeks SG, Rinaldo C, Kuller LH, Justice A, Freiberg M. HIV Status, Burden of Comorbid Disease, and Biomarkers of Inflammation, Altered Coagulation, and Monocyte Activation. Clinical Infectious Diseases 2012, 55: 126-136. PMID: 22534147, PMCID: PMC3493182, DOI: 10.1093/cid/cis406.Peer-Reviewed Original ResearchConceptsBiomarkers of inflammationVeterans Aging Cohort StudyAltered coagulationMonocyte activationUninfected veteransCardiovascular diseaseElevated biomarkersComorbid conditionsHigh prevalenceCD4 cell countElevated IL-6Aging Cohort StudyOngoing HIV replicationPrevalent cardiovascular diseaseHIV-1 RNAHuman immunodeficiency virusCopies/mLElevated sCD14More dyslipidemiaCD4 countHepatitis CCohort studyComorbid diseasesCurrent smokingHIV infectionDoes an Index Composed of Clinical Data Reflect Effects of Inflammation, Coagulation, and Monocyte Activation on Mortality Among Those Aging With HIV?
Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, Goetz MB, Fiellin DA, Vanasse GJ, Butt AA, Rodriguez-Barradas MC, Gibert C, Oursler KA, Deeks SG, Bryant K, Team T. Does an Index Composed of Clinical Data Reflect Effects of Inflammation, Coagulation, and Monocyte Activation on Mortality Among Those Aging With HIV? Clinical Infectious Diseases 2012, 54: 984-994. PMID: 22337823, PMCID: PMC3297653, DOI: 10.1093/cid/cir989.Peer-Reviewed Original ResearchConceptsHIV-1 RNANet reclassification improvementHepatitis C virusD-dimerIL-6VACS IndexMonocyte activationVeterans Aging Cohort Study (VACS) IndexHuman immunodeficiency virus type 1 (HIV-1) RNAFIB-4 indexGlomerular filtration rateMarkers of liverRoutine clinical variablesCopies/mLPrediction of mortalityEffects of inflammationHCV statusAntiretroviral therapyCD4 countRenal injuryReclassification improvementClinical variablesC-statisticC virusFiltration rate
2011
Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America
Abraham AG, Lau B, Deeks S, Moore RD, Zhang J, Eron J, Harrigan R, Gill MJ, Kitahata M, Klein M, Napravnik S, Rachlis A, Rodriguez B, Rourke S, Benson C, Bosch R, Collier A, Gebo K, Goedert J, Hogg R, Horberg M, Jacobson L, Justice A, Kirk G, Martin J, McKaig R, Silverberg M, Sterling T, Thorne J, Willig J, Gange SJ, AIDS F. Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. American Journal Of Epidemiology 2011, 174: 727-735. PMID: 21813792, PMCID: PMC3202147, DOI: 10.1093/aje/kwr141.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusDrug resistanceGenotype testNorth American AIDS Cohort CollaborationHuman immunodeficiency virus drug resistanceGenotypic Resistance Interpretation AlgorithmClinic-based cohortAntiretroviral drug classesAntiretroviral drug resistanceResistance interpretation algorithmsVirus drug resistanceCopies/mLHIV drug resistanceClinical knowledgeDrug resistance mutationsPrevalence of resistanceCohort CollaborationViral loadImmunodeficiency virusAntiretroviral drugsDrug classesClinical carePatientsPrevalenceMultiple imputation methodRisk of Heart Failure With Human Immunodeficiency Virus in the Absence of Prior Diagnosis of Coronary Heart Disease
Butt AA, Chang CC, Kuller L, Goetz MB, Leaf D, Rimland D, Gibert CL, Oursler KK, Rodriguez-Barradas MC, Lim J, Kazis LE, Gottlieb S, Justice AC, Freiberg MS. Risk of Heart Failure With Human Immunodeficiency Virus in the Absence of Prior Diagnosis of Coronary Heart Disease. JAMA Internal Medicine 2011, 171: 737-743. PMID: 21518940, PMCID: PMC3687533, DOI: 10.1001/archinternmed.2011.151.Peer-Reviewed Original ResearchConceptsIncident HF eventsHeart failureCoronary heart diseaseCopies/mLRisk factorsHIV infectionHF eventsHeart diseaseHigh riskVeterans Aging Cohort Study Virtual CohortHIV-1 RNA levelsRisk of HFCoronary heart disease eventsHuman immunodeficiency virus (HIV) infectionRNA levelsIncident heart failureOngoing viral replicationRetrospective cohort studyHeart disease eventsImmunodeficiency virus infectionHuman immunodeficiency virusVACS-VCVeteran EnrolleesCohort studyPrior diagnosis
2005
Estimating the proportion of patients infected with HIV who will die of comorbid diseases
Braithwaite RS, Justice AC, Chang CC, Fusco JS, Raffanti SR, Wong JB, Roberts MS. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. The American Journal Of Medicine 2005, 118: 890-898. PMID: 16084183, DOI: 10.1016/j.amjmed.2004.12.034.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusComorbid diseasesCombination therapyNaïve human immunodeficiency virusNon-HIV mortalityEffective antiretroviral therapyCells/mm3Proportion of patientsSeparate patient cohortsCopies/mLProportion of deathsLikelihood of deathAntiretroviral therapyObservational cohortHIV infectionTreatment failureViral loadImmunodeficiency virusMean agePatient cohortPatientsSubsequent deathPhenotypic resistanceTherapyCohort
2004
Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy
Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D’Aquila R, Mangialardi WJ, Fusco GP. Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2004, 37: 1147-1154. PMID: 15319674, DOI: 10.1097/01.qai.0000136738.24090.d0.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCopies/mLBaseline HIV-1 RNA levelsNew AIDSCopies/Moderate viremiaRNA levelsPlasma HIV-1 RNAAIDS-defining diagnosisAntiretroviral therapy historyActive antiretroviral therapyUnited States cohortHIV-1 RNACells/Proportional hazards modelCD4 count changesImmunologic deteriorationAntiretroviral therapyCD4 countPrior AIDSUndetectable viremiaViral suppressionImmunologic statusHIV infectionClinical benefit
2003
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies
Chêne G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. The Lancet 2003, 362: 679-686. PMID: 12957089, DOI: 10.1016/s0140-6736(03)14229-8.Peer-Reviewed Original ResearchConceptsCells/microLHIV-1 RNACopies/mLCD4 countHazard ratioHIV-1Current CD4 cell countPotent antiretroviral therapyCD4 cell countTreatment-naive patientsYears of followActive antiretroviral treatmentHigh-risk stratumSubsequent disease progressionLow-risk stratumProbability of progressionBaseline CD4Antiretroviral therapyCohort studyAntiretroviral treatmentMonth 6Viral loadClinical progressionPrognostic importanceProspective study